Almenoff S. June's most recent trade in Tenax Therapeutics Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc | June S. Almenoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | June S. Almenoff | Director | Purchase of securities on an exchange or from another person at price $ 7.52 per share. | 17 Nov 2025 | 1,900 | 1,993 (0%) | 0% | 7.5 | 14,280 | Common Stock |
| Tenax Therapeutics Inc | June S. Almenoff | Director | Purchase of securities on an exchange or from another person at price $ 7.52 per share. | 17 Nov 2025 | 1,900 | 1,993 (0%) | 0% | 7.5 | 14,280 | Common Stock |
| Tenax Therapeutics Inc | June S. Almenoff | Director | Purchase of securities on an exchange or from another person at price $ 7.15 per share. | 17 Nov 2025 | 93 | 93 (0%) | 0% | 7.2 | 665 | Common Stock |
| Tenax Therapeutics Inc | June S. Almenoff | Director | Purchase of securities on an exchange or from another person at price $ 7.15 per share. | 17 Nov 2025 | 93 | 93 (0%) | 0% | 7.2 | 665 | Common Stock |
| Tenax Therapeutics Inc | S. June Almenoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Tenax Therapeutics Inc | Almenoff S. June | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | 12 Nov 2024 | 500 | 500 | - | 12.5 | 6,250 | Common Stock | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | 12 Nov 2024 | 500 | 1,000 | - | 13 | 6,500 | Common Stock | |
| Avalo Therapeutics Inc | June S. Almenoff | Director | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | ||
| Avalo Therapeutics Inc | Almenoff S. June | Director | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 30 Jun 2023 | 4,575 | 4,575 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 31 Mar 2023 | 1,167 | 1,167 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 30 Dec 2022 | 410 | 410 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 30 Sep 2022 | 605 | 605 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 30 Jun 2022 | 4,338 | 4,338 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 31 Mar 2022 | 2,985 | 2,985 | - | - | Stock Option (Right to Buy) | ||
| Avalo Therapeutics Inc | June S. Almenoff | Director | 10 Nov 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) |